DoD study data is literally any day now!
Fellow investors, I've been watching Immuron closely and everything points towards a massive re-rating. While many are focused on the past, the current flow of positive catalysts is undeniable. My conviction is extremely high right now, and here's why
Travelan® DoD study: Results landing any day now
This is the big one, folks. The company has repeatedly stated in announcements (October 2 and October 20, 2025) that topline data from the large-scale US military field study was expected in October 2025.
We are in late October right now. This means the data drop could happen at any moment.
What's at stake: A positive result from this 866-participant study could validate Travelan® on a huge scale and be a game-changer for formal FDA approval. It would pave the way for an "End-of-Phase 2" meeting with the FDA in the first half of 2026 to plan a Phase 3 program.
Massive market potential: A Lumanity assessment projects a potential yearly US revenue of US$102 million for Travelan®. Positive data moves us closer to that reality.
IMM-529: IND submitted for a $400M market
The IMM-529 program is also de-risking rapidly. Immuron announced the IND submission to the FDA on October 8, 2025. This is a massive tick-the-box milestone.
Next step: Phase 2 trial. The company is now planning to start a Phase 2 trial in the first half of 2026.
Huge market potential: For this drug targeting C. difficile, independent analysis projects potential peak annual US revenue of US$400 million.
ProIBS®: Early commercial success
While the clinical programs build, the commercial side is already firing.
Record Q1 sales: Q1 FY26 sales were up 34% year-over-year.
Strong Aussie growth: The launch of ProIBS® in Australia (announced October 24, 2025) adds a new revenue stream to complement strong Travelan® sales.
Conclusion: Why I'm more bullish than ever
The stars are aligning for Immuron. We have immediate, near-term catalysts (DoD data any day) coupled with medium-term catalysts (Phase 2 plans for Travelan® and IMM-529). All of this is underpinned by growing commercial revenue. The narrative is shifting from a speculative R&D story to a commercial biopharma with multiple revenue drivers. The market has yet to fully appreciate this, which is why I believe the potential for a significant re-rate is higher than ever.
The silence around the DoD data is deafening. Let's hope for an announcement soon.
Not financial advice. DYOR.
Add to My Watchlist
What is My Watchlist?
